Glenmark Life Sciences

The Mumbai-based drug maker's profit rose to 1.05 billion rupees ($12.86 million) in the three months ended Dec. 31, from 1.04 billion rupees a year ago

Merck's anti-diabetic molecule sitagliptin retains 81% market share in value terms

Company promoters bought shares even when they held more than 75 per cent

Glenmark had conducted the study on 306 vaccinated and unvaccinated adults with symptomatic mild Covid-19 disease across 20 clinical trial sites in India

Glenmark Pharmaceuticals on Monday said it has launched a novel fixed-dose combination (FDC) of Teneligliptin, with Pioglitazone in India for adults with uncontrolled Type 2 diabetes. Glenmark has launched this FDC under the brand name Zita Plus Pio, which contains Teneligliptin (20 mg) and Pioglitazone (15 mg), to be taken once a day, the company said in a statement. Diabetes is a key area of focus for Glenmark; a pioneer in providing access to the latest treatment options to diabetic patients in India. We are delighted to introduce this novel Zita Plus Pio, which is the first of its kind in India; offering a world-class and affordable treatment option to adult diabetic patients, Glenmark Pharmaceuticals Group Vice President & Head, India Formulations Alok Malik said. Glenmark claimed it is the "first company in India to market the innovative FDC of Teneligliptin + Pioglitazone, which is approved by the DCGI (Drug Controller General of India)" "This fixed-dose combination will be

Glenmark Life Sciences on Friday said its net profit increased 25 per cent to Rs 101 crore in the first quarter ended June 30, 2021. The company had reported a net profit of Rs 81 crore in April-June 2020-21. Revenue from operations rose to Rs 525 crore as compared with Rs 3,970 crore in the year-ago period. "At Glenmark Life Sciences, we are delighted to announce our first financial result post listing. Being in the healthcare industry, it was important that we continue our services & operations uninterrupted, despite several challenges during the second wave of the pandemic. "Today we have embarked on a good start in Q1 FY22, with the business delivering a strong growth," Glenmark Life Sciences MD & CEO Yasir Rawjee said in a statement. The company's generic API (active pharmaceutical ingredients) business has delivered robust growth across all geographies, and increased demand in both regulated and emerging markets have fuelled this growth, he added. "However, the CDMO ...

On Friday, August 6, 2021, the company had made a quiet debut on the bourses as the shares listed at Rs 751.10 on the BSE

Market observers said HNIs had placed leveraged bets, and lost big as their break even cost was more than Rs 850 per share

Post listing, the stock moved higher to Rs 799.50, 11 per cent higher against issue price